Summary
Objectives To explore the efficacy of fumarate vonoradine in patients with throat reflux disease (LPRD). Methods Retrospective analysis of clinical data on 89 patients who were outpatient visits from June 2020 to January 2022, including 45 men, 44 women, and 18-77 (45.54 ± 13.53) years old. According to the reflux symptom index (RSI) and the anti-fluid sign score (RFS), the above patients are proposed to be LPRD. Among them, 45 patients in the vonoraxon fumarate group (oral fumarate vonorason, 20 mg, qd), and 44 patients in the esomerazole group (oral esomerazole, 20 mg, bid), all of which were treated for 8 weeks. After treatment, their RSI and RFS were evaluated to compare their changes. Statistical analysis using SPSS 18.0 software. There were no significant differences in the sex, age, RSI and RFS of the first two groups of patients. The signs and symptoms of the two groups of patients were significantly relieved. Fumarate vonoraxone group: pre-treatment RSI is (12.62 ± 7.18) and post-treatment RSI is (4.74 ± 3.87), t = 6.91, P <0.001; RFS before treatment (10.78 ± 2.29) and post-treatment RFS (8.24 ± 2.45), t = 7.06, P <0.001. The esomerazole group: pre-treatment RSI is (13.27 ± 6.95) and post-treatment RSI is (6.02 ± 4.28), t = 7.50, P <0.001; RFS before treatment (10.59 ± 3.14) and post-treatment RFS (8.14 ± 3.30) t = 5.41, No significant difference in treatment efficiency in P <0.001,2 groups of patients (66.7% in the vonorazolet fumarate group and 77.3% in the esomerazole group, χ 2 =1.443, P = 0.486). 结论Fumarate vonora is effective in alleviating the symptoms and symptoms of LPRD patients, and its treatment effect is not inferior to esomerazole, which can be used as a supplement to PPI treatment.
| 
20